Hamostaseologie最新文献_第2页

From Case Reports to Cohort Studies: The Many Faces of Clinical Research in Thrombosis and Haemostasis. 从病例报告到队列研究：血栓和止血临床研究的多个方面。

IF 2.4 4区医学

Hamostaseologie Pub Date : 2026-04-01 Epub Date: 2026-04-21 DOI: 10.1055/a-2785-1481

Florian Langer, Heiko Rühl, Manuela Albisetti

引用次数: 0

Veranstaltung des BDDH auf der 70. Jahrestagung der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) in Bonn am 17.02.2026. 第70届BDDH会议。德国血栓与止血学会（GTH）年会于2026年2月17日在波恩举行。

IF 2.4 4区医学

Hamostaseologie Pub Date : 2026-04-01 Epub Date: 2026-04-21 DOI: 10.1055/a-2785-1462

Jürgen Koscielny, Christoph Sucker

引用次数: 0

Die Gesellschaft für Thrombose- und Hämostaseforschung e.V. informiert. 血栓和止血研究协会。

IF 2.4 4区医学

Hamostaseologie Pub Date : 2026-04-01 Epub Date: 2026-04-21 DOI: 10.1055/a-2785-1601

Florian Langer

引用次数: 0

Beschleunigte Gefäßalterung nach COVID-19-Infektion (CARTESIAN-Studie). “COVID-19感染后血管加速（Cartesian）”。

IF 2.4 4区医学

Hamostaseologie Pub Date : 2026-04-01 Epub Date: 2026-04-21 DOI: 10.1055/a-2825-4244

引用次数: 0

Postviral Anti-PF4 Immunothrombosis in Children: A Narrative Review with Practical Guidance. 儿童病毒后抗pf4免疫血栓形成：具有实践指导的叙述性回顾。

IF 2.4 4区医学

Hamostaseologie Pub Date : 2026-03-13 DOI: 10.1055/a-2791-8607

Günalp Uzun, Martin Olivieri, Tamam Bakchoul

{"title":"Postviral Anti-PF4 Immunothrombosis in Children: A Narrative Review with Practical Guidance.","authors":"Günalp Uzun, Martin Olivieri, Tamam Bakchoul","doi":"10.1055/a-2791-8607","DOIUrl":"https://doi.org/10.1055/a-2791-8607","url":null,"abstract":"Postviral antiplatelet factor 4 (PF4) immunothrombosis is an emerging pediatric entity characterized by thrombocytopenia, thrombosis, and markedly elevated D-dimer levels and anti-PF4 antibodies. It shares immunopathologic features with vaccine-induced immune thrombotic thrombocytopenia but arises after natural infection, most often adenoviral infection. We reviewed pediatric cases and mechanistic studies identified through PubMed and reference screening (latest search: November 20, 2025), with a focus on pathophysiology, differential diagnosis, laboratory evaluation, and treatment. We identified 10 pediatric patients, with a reported mortality rate of 20%. Children typically presented with acute severe headache, focal neurological deficits, and thrombocytopenia 5-14 days after recent viral illness. All reported cases had markedly increased D-dimers. Rapid immunoassays for heparin-induced thrombocytopenia were often negative; PF4-specific enzyme-linked immunosorbent assay and PF4-enhanced functional assays were positive. Treatments in published cases included anticoagulation (9/10 cases), intravenous immunoglobulin (5/10 cases), and plasma exchange therapy (3/10 cases). On the basis of these findings and mechanistic parallels, we propose a diagnostic and therapeutic approach, acknowledging the limited evidence base. In conclusion, postviral anti-PF4 immunothrombosis in children, although rare, is potentially fatal and likely underrecognized. Further research is needed to establish standardized diagnostic criteria and evidence-based treatment protocols.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147460965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of Soluble and Humoral Immunological Parameters During Re-exposure with rFVIIIFc after History of Inhibitors. 抑制剂史后再暴露于rfviii - ifc时的可溶性和体液免疫参数分析。

IF 2.4 4区医学

Hamostaseologie Pub Date : 2026-02-24 DOI: 10.1055/a-2722-8734

Anja Schmidt, Stephan Schultze-Strasser, Diana Stichel, Aleksander Orlowski, Christine Heller, Christoph Königs

{"title":"Analysis of Soluble and Humoral Immunological Parameters During Re-exposure with rFVIIIFc after History of Inhibitors.","authors":"Anja Schmidt, Stephan Schultze-Strasser, Diana Stichel, Aleksander Orlowski, Christine Heller, Christoph Königs","doi":"10.1055/a-2722-8734","DOIUrl":"https://doi.org/10.1055/a-2722-8734","url":null,"abstract":"Little is known on the mechanisms of tolerance to factor VIII (FVIII) in haemophilia A (HA) patients. To identify immunological markers in tolerance development, samples from two patients with HA treated with rFVIIIFc after a history of inhibitors were analyzed. The patients have been followed closely during re-exposure with FVIII as part of immune tolerance induction. Plasma samples were analyzed for FVIII inhibitors and FVIII-specific antibodies. Analysis of further immunological markers was performed for patient 2 using peripheral blood mononuclear cells (PBMCs); additionally, cytokines in cell culture media were quantified. Laboratory data were compared to pharmacological parameters and clinical outcome.Both patients showed a decline in FVIII recovery (exposure day [ED] 12 for patient 1, ED 25 for patient 2). During that time patient 2 was positive for lupus anticoagulants and a low amount of FVIII-specific antibodies was detectable in ELISA. However, specificity could not be verified by competition and antibodies disappeared again after ED 25. Patient 1 developed FVIII-specific antibodies of subclass IgG4 after ED 229. Antibodies were mainly directed against the FVIII light chain. FVIII-responsive CD4+ T-cells were detectable in the patient's PBMCs. Additionally, PMBCs showed an elevated production of IL-23 and TNF-α when stimulated with FVIII.A prospective analysis of the described parameters might help to identify the onset of an immune response. Even though the number of analyzed patients is low, the detailed analyses may help to further understand the development of tolerance to FVIII and to define starting points for further interventions against treatment complications through inhibitor development in HA.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thrombophilia Testing in Women and Adolescent Girls-Position Paper from the Standing Committee on Women's Health Issues of the Society for Thrombosis and Haemostasis Research (GTH). 血栓形成和止血研究协会（GTH）妇女健康问题常设委员会的立场文件：妇女和少女的血栓形成试验。

IF 2.4 4区医学

Hamostaseologie Pub Date : 2026-02-12 DOI: 10.1055/a-2780-3709

Birgit Linnemann, Rupert Bauersachs, Frauke Bergmann, Christina Hart, Edelgard Lindhoff-Last, Hannelore Rott, Christian Pfrepper

{"title":"Thrombophilia Testing in Women and Adolescent Girls-Position Paper from the Standing Committee on Women's Health Issues of the Society for Thrombosis and Haemostasis Research (GTH).","authors":"Birgit Linnemann, Rupert Bauersachs, Frauke Bergmann, Christina Hart, Edelgard Lindhoff-Last, Hannelore Rott, Christian Pfrepper","doi":"10.1055/a-2780-3709","DOIUrl":"https://doi.org/10.1055/a-2780-3709","url":null,"abstract":"Hereditary and acquired thrombophilia increase the risk of first-time and recurrent venous thromboembolism (VTE). In unselected VTE cohorts, thrombophilic disorders are detected in approximately 40-50% of cases. The probability of a positive test result is higher in patients with a positive family history and VTE manifestation at a young age. The diagnosis of thrombophilia does not necessarily have consequences for further treatment. On the other hand, there are several aspects specific to women where knowledge of thrombophilia influences treatment decisions. The aim of this paper is to describe the various situations specific to women, to present current evidence, and to make recommendations regarding the usefulness and scope of thrombophilia screening. To this end, a panel of 18 experts was assembled within the Standing Committee on Women's Health Issues of the Society for Thrombosis and Haemostasis Research (GTH), which developed recommendations as part of a Delphi process.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146183516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tramadol and Its Influence on Platelet Function - An Ex Vivo Study. 曲马多及其对血小板功能影响的体外研究。

IF 2.4 4区医学

Hamostaseologie Pub Date : 2026-02-12 DOI: 10.1055/a-2780-3616

Philipp Zoidl, Helmar Bornemann-Cimenti, Michael Eichinger, Michael Eichlseder, Lioba Heuschneider, Nikolaus Schreiber, Paul Zajic, Gudrun Rumpold-Seitinger, Florian Prüller, Gabriel Honnef

{"title":"Tramadol and Its Influence on Platelet Function - An Ex Vivo Study.","authors":"Philipp Zoidl, Helmar Bornemann-Cimenti, Michael Eichinger, Michael Eichlseder, Lioba Heuschneider, Nikolaus Schreiber, Paul Zajic, Gudrun Rumpold-Seitinger, Florian Prüller, Gabriel Honnef","doi":"10.1055/a-2780-3616","DOIUrl":"https://doi.org/10.1055/a-2780-3616","url":null,"abstract":"Tramadol, a weak μ-opioid receptor agonist and a widely used analgesic, also inhibits serotonin and norepinephrine reuptake, which could potentially influence platelet function. While the bleeding risk of selective serotonin reuptake inhibitors is well documented, the impact of tramadol on platelet aggregation, despite its widespread use, remains underexplored. Therefore, this study aims to elucidate tramadol's effect on platelet function. This single-center laboratory study involved healthy volunteers at the Medical University of Graz, Austria. Platelet function was assessed using light transmission aggregometry following the addition of tramadol in increasing concentrations (0, 500, 1500, 4500, and 9000 ng/mL) to blood samples. Baseline and post-tramadol-addition platelet aggregation was measured using adenosine diphosphate-induced (ADP), ristocetin-induced, and thrombin-receptor activating peptide-induced (TRAM) aggregation. Statistical analysis employed the Friedman test. Seven healthy volunteers could be included in the final analysis. Platelet aggregation was assessed after ex vivo addition of tramadol (500-9000 ng/mL). No significant differences in aggregation percentages were observed between tramadol concentrations and baseline inducing activation with ADP, ristocetin, or TRAP. These findings suggest that tramadol, at therapeutic and supratherapeutic concentrations, does not significantly impair platelet function in most individuals. This supports the general safety profile of tramadol regarding platelet aggregation.Tramadol appears safe concerning platelet function. Further research with larger cohorts is warranted to confirm these results and investigate potential interindividual variability in response to tramadol.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146183466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Frequency of T Regulatory Cells Subpopulations in Hemophilia A Patients with Inhibitors. 使用抑制剂的A型血友病患者T调节细胞亚群频率

IF 2.4 4区医学

Hamostaseologie Pub Date : 2026-02-02 DOI: 10.1055/a-2698-0263

Rodrigo Arreola-Díaz, Jesús Hernández-Juárez, Tania Ricardo-Moreno, Luvia E Sánchez-Torres, Jaime García-Chávez, Jorge Vela-Ojeda, Víctor Manuel Domínguez-Reyes, Abraham Majluf-Cruz

{"title":"Frequency of T Regulatory Cells Subpopulations in Hemophilia A Patients with Inhibitors.","authors":"Rodrigo Arreola-Díaz, Jesús Hernández-Juárez, Tania Ricardo-Moreno, Luvia E Sánchez-Torres, Jaime García-Chávez, Jorge Vela-Ojeda, Víctor Manuel Domínguez-Reyes, Abraham Majluf-Cruz","doi":"10.1055/a-2698-0263","DOIUrl":"https://doi.org/10.1055/a-2698-0263","url":null,"abstract":"Hemophilia A is a hemorrhagic disease caused by a quantitative/qualitative deficiency of factor VIII. It is classified as severe, moderate, or mild based on its residual procoagulant activity. Long-term administration of FVIII promotes the development of neutralizing antibodies (inhibitors) in almost 30% of patients with the severe form of the disease. Currently, the role of regulatory T cells in the development of these antibodies is conflicting. Accordingly, the aim of this study was to determine the percentage of regulatory T cells subpopulations by flow cytometry in 10 healthy subjects, 15 patients with severe hemophilia without inhibitors, and 8 with inhibitors. No significant differences in the frequency of regulatory T cells subpopulations were found between hemophilia A patients with inhibitors versus hemophilia A patients without inhibitors or healthy subjects. Our results suggest that the role of the regulatory T cells populations on the development of inhibitors in adult patients with hemophilia A is questionable. However, further analysis of the etiological relevance of these cells requires future research.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146108412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GTH 2026: Connected Science - Advanced Solutions. GTH 2026：互联科学-先进解决方案。

IF 2.4 4区医学

Hamostaseologie Pub Date : 2026-02-01 Epub Date: 2026-02-19 DOI: 10.1055/a-2661-6103

Johannes Oldenburg, Bernd Pötzsch

引用次数: 0